NEW YORK (360Dx) – French diagnostic and theranostics firm Theradiag today said it has raised more than €4 million ($4.4 million) after issuing shares to "a specific category of persons."

Theradiag sold 1.7 million new shares at €2.30 per share. The shares were issued following an accelerated bookbuilding process, the firm said, adding the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.